RT Journal Article SR Electronic T1 Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders JF BMJ Open Gastroenterology FD BMJ Publishing Group Ltd SP e000087 DO 10.1136/bmjgast-2016-000087 VO 3 IS 1 A1 Hani Sbahi A1 Jack A Di Palma YR 2016 UL http://bmjopengastro.bmj.com//content/3/1/e000087.abstract AB The process of stool transfer from healthy donors to the sick, known as faecal microbiota transplantation (FMT), has an ancient history. However, only recently researchers started investigating its applications in an evidence-based manner. Current knowledge of the microbiome, the concept of dysbiosis and results of preliminary research suggest that there is an association between gastrointestinal bacterial disruption and certain disorders. Researchers have studied the effects of FMT on various gastrointestinal and non-gastrointestinal diseases, but have been unable to precisely pinpoint specific bacterial strains responsible for the observed clinical improvement or futility of the process. The strongest available data support the efficacy of FMT in the treatment of recurrent Clostridium difficile infection with cure rates reported as high as 90% in clinical trials. The use of FMT in other conditions including inflammatory bowel disease, functional gastrointestinal disorders, obesity and metabolic syndrome is still controversial. Results from clinical studies are conflicting, which reflects the gap in our knowledge of the microbiome composition and function, and highlights the need for a more defined and personalised microbial isolation and transfer.